Literature DB >> 15711606

Association between hormonal genetic polymorphisms and early-onset prostate cancer.

M S Forrest1, S M Edwards, R Houlston, Z Kote-Jarai, T Key, N Allen, M A Knowles, F Turner, A Ardern-Jones, A Murkin, S Williams, R Oram, D T Bishop, R A Eeles.   

Abstract

We investigated the association between seven polymorphisms in four candidate genes involved in vitamin D and androgen metabolism with early-onset prostate cancer (CaP) risk. The polymorphisms were genotyped in 288 UK males who were diagnosed with CaP at the age of 55 y or younger and up to 700 population-based controls. An additional 50 cases (not selected for age) and 76 controls were also genotyped. Short (< or =22 repeats) AR (CAG)(n) repeats were associated with a significantly reduced risk of early onset CaP (OR 0.68, 95% CI 0.50-0.91) compared with men with long (> 22) repeats. Men homozygous for the leucine variant of SRD5A2 p.89V > L were also found to be at a significantly increased risk of CaP compared with men who were homozygous for the valine allele (OR 1.84, 95% CI 1.15-2.98). No associations were found with the AR (GGC)(n), CYP17 Msp A1 I, VDR Taq I, SRD5A2 (TA)(n) and p.49A >T polymorphisms and CaP risk. These findings suggest that common polymorphisms in the AR and SRD5A2 genes may be associated with early-onset CaP in British men.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15711606     DOI: 10.1038/sj.pcan.4500785

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  17 in total

1.  No association between the SRD5A2 gene A49T missense variant and prostate cancer risk: lessons learned.

Authors:  C Leigh Pearce; David J Van Den Berg; Nick Makridakis; Juergen K V Reichardt; Ronald K Ross; Malcolm C Pike; Laurence N Kolonel; Brian E Henderson
Journal:  Hum Mol Genet       Date:  2008-05-10       Impact factor: 6.150

2.  Steroid 5-alpha-reductase type 2 (SRD5A2) V89L and A49T polymorphisms and sporadic prostate cancer risk: a meta-analysis.

Authors:  Qiaoxin Li; Yao Zhu; Jing He; Mengyun Wang; Meiling Zhu; Tingyan Shi; Lixin Qiu; Dingwei Ye; Qingyi Wei
Journal:  Mol Biol Rep       Date:  2013-01-01       Impact factor: 2.316

3.  GGN repeat length and GGN/CAG haplotype variations in the androgen receptor gene and prostate cancer risk in south Indian men.

Authors:  Krishnaswamy Vijayalakshmi; Kumarasamy Thangaraj; Singh Rajender; Venkatesan Vettriselvi; Perumal Venkatesan; Sunil Shroff; K N Vishwanathan; Solomon F D Paul
Journal:  J Hum Genet       Date:  2006-09-13       Impact factor: 3.172

4.  Androgen receptor CAG repeat length and association with prostate cancer risk: results from the prostate cancer prevention trial.

Authors:  Douglas K Price; Cindy H Chau; Cathee Till; Phyllis J Goodman; Caitlin E Baum; Sandy B Ockers; Bevin C English; Lori Minasian; Howard L Parnes; Ann W Hsing; Juergen K V Reichardt; Ashraful Hoque; Catherine M Tangen; Alan R Kristal; Ian M Thompson; William D Figg
Journal:  J Urol       Date:  2010-10-16       Impact factor: 7.450

5.  SRD5A2 and HSD3B2 polymorphisms are associated with prostate cancer risk and aggressiveness.

Authors:  Christine Neslund-Dudas; Cathryn H Bock; Kristin Monaghan; Nora L Nock; James J Yang; Andrew Rundle; Deliang Tang; Benjamin A Rybicki
Journal:  Prostate       Date:  2007-11-01       Impact factor: 4.104

Review 6.  Genetic variation: effect on prostate cancer.

Authors:  Tristan M Sissung; Douglas K Price; Marzia Del Re; Ariel M Ley; Elisa Giovannetti; William D Figg; Romano Danesi
Journal:  Biochim Biophys Acta       Date:  2014-09-06

7.  CYP17 T27C polymorphism and prostate cancer risk: a meta-analysis based on 31 studies.

Authors:  Bingbing Wei; Yunyun Zhang; Bo Xi; Junkai Chang; Jinming Bai; Jiantang Su
Journal:  J Biomed Res       Date:  2010-05

Review 8.  Association between polymorphic CAG repeat lengths in the androgen receptor gene and susceptibility to prostate cancer: A systematic review and meta-analysis.

Authors:  Zhiqiang Qin; Xiao Li; Peng Han; Yuxiao Zheng; Hanyu Liu; Jingyuan Tang; Chengdi Yang; Jianzhong Zhang; Kunpeng Wang; Xiaokang Qi; Min Tang; Wei Wang; Wei Zhang
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

9.  Impact of Age at Diagnosis on Outcomes in Men with Castrate-Resistant Prostate Cancer (CRPC).

Authors:  Michael R Humphreys; Kimberly A Fernandes; Srikala S Sridhar
Journal:  J Cancer       Date:  2013-03-21       Impact factor: 4.207

10.  Androgen receptor polyglutamine repeat number: models of selection and disease susceptibility.

Authors:  Calen P Ryan; Bernard J Crespi
Journal:  Evol Appl       Date:  2012-06-11       Impact factor: 5.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.